128 related articles for article (PubMed ID: 35253621)
1. An integrated computational approach to screening of alkaloids inhibitors of TBX3 in breast cancer cell lines.
Paul A; Limon MBH; Hossain MM; Raza MT
J Biomol Struct Dyn; 2023 Apr; 41(7):3025-3041. PubMed ID: 35253621
[TBL] [Abstract][Full Text] [Related]
2. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
3. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB
BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211
[TBL] [Abstract][Full Text] [Related]
4. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.
Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB
J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731
[TBL] [Abstract][Full Text] [Related]
5. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines.
Fan W; Huang X; Chen C; Gray J; Huang T
Cancer Res; 2004 Aug; 64(15):5132-9. PubMed ID: 15289316
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific promotion of breast cancer tumorigenicity by TBX3 involves induction of angiogenesis.
Krstic M; Hassan HM; Kolendowski B; Hague MN; Anborgh PH; Postenka CO; Torchia J; Chambers AF; Tuck AB
Lab Invest; 2020 Mar; 100(3):400-413. PubMed ID: 31570773
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
8. The special stemness functions of Tbx3 in stem cells and cancer development.
Dong L; Lyu X; Faleti OD; He ML
Semin Cancer Biol; 2019 Aug; 57():105-110. PubMed ID: 30268432
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer.
Amir S; Simion C; Umeh-Garcia M; Krig S; Moss T; Carraway KL; Sweeney C
Br J Cancer; 2016 May; 114(10):1125-34. PubMed ID: 27100732
[TBL] [Abstract][Full Text] [Related]
10. The roles and regulation of TBX3 in development and disease.
Khan SF; Damerell V; Omar R; Du Toit M; Khan M; Maranyane HM; Mlaza M; Bleloch J; Bellis C; Sahm BDB; Peres J; ArulJothi KN; Prince S
Gene; 2020 Feb; 726():144223. PubMed ID: 31669645
[TBL] [Abstract][Full Text] [Related]
11. TBX3 over-expression causes mammary gland hyperplasia and increases mammary stem-like cells in an inducible transgenic mouse model.
Liu J; Esmailpour T; Shang X; Gulsen G; Liu A; Huang T
BMC Dev Biol; 2011 Oct; 11():65. PubMed ID: 22039763
[TBL] [Abstract][Full Text] [Related]
12. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
13. [Expression of TBX3 mRNA and its role in the pathogenesis and metastasis of breast cancer].
Chen ZH; Lü GM; Ji TH
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):87-9. PubMed ID: 19218121
[TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer.
Anbuselvam M; Easwaran M; Meyyazhagan A; Anbuselvam J; Bhotla HK; Sivasubramanian M; Annadurai Y; Kaul T; Pappusamy M; Balasubramanian B
J Biomol Struct Dyn; 2021 Aug; 39(12):4462-4471. PubMed ID: 32567493
[TBL] [Abstract][Full Text] [Related]
15. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies.
Agarwal S; Dixit A; Kashaw SK
J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678
[TBL] [Abstract][Full Text] [Related]
16. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
[TBL] [Abstract][Full Text] [Related]
17.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
18. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
[TBL] [Abstract][Full Text] [Related]
19. TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-β1/Smad signaling.
Lee YJ; Park JH; Oh SM
Biochem Biophys Res Commun; 2020 Jan; 522(1):270-277. PubMed ID: 31757421
[TBL] [Abstract][Full Text] [Related]
20. Carboxymuconolactone decarboxylase is a prospective molecular target for multi-drug resistant Acinetobacter baumannii-computational modeling, molecular docking and dynamic simulation studies.
Rana S; Skariyachan S; Uttarkar A; Niranjan V
Comput Biol Med; 2023 May; 157():106793. PubMed ID: 36944292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
